Mesa Laboratories, Inc. (NASDAQ:MLAB – Get Free Report) CFO John Sakys sold 2,827 shares of Mesa Laboratories stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $253,016.50. Following the completion of the transaction, the chief financial officer directly owned 19,785 shares of the company’s stock, valued at approximately $1,770,757.50. This represents a 12.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
John Sakys also recently made the following trade(s):
- On Tuesday, June 16th, John Sakys sold 1,223 shares of Mesa Laboratories stock. The stock was sold at an average price of $101.27, for a total transaction of $123,853.21.
Mesa Laboratories Stock Up 1.1%
MLAB stock traded up $1.05 during trading on Tuesday, hitting $94.28. 64,805 shares of the stock traded hands, compared to its average volume of 138,158. The stock has a market cap of $520.90 million, a price-to-earnings ratio of 78.57 and a beta of 0.94. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. Mesa Laboratories, Inc. has a 1 year low of $55.45 and a 1 year high of $113.99. The firm’s 50 day moving average is $101.95 and its two-hundred day moving average is $90.98.
Mesa Laboratories Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Friday, May 29th were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Friday, May 29th. Mesa Laboratories’s payout ratio is presently 53.33%.
Wall Street Analyst Weigh In
Separately, Weiss Ratings downgraded Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $94.00.
Check Out Our Latest Stock Analysis on Mesa Laboratories
Hedge Funds Weigh In On Mesa Laboratories
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Mesa Laboratories by 5,366.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Mesa Laboratories during the fourth quarter valued at approximately $27,000. Kestra Advisory Services LLC purchased a new stake in Mesa Laboratories in the fourth quarter worth approximately $55,000. BNP Paribas Financial Markets boosted its holdings in Mesa Laboratories by 115.3% in the second quarter. BNP Paribas Financial Markets now owns 786 shares of the medical instruments supplier’s stock worth $74,000 after purchasing an additional 421 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Mesa Laboratories by 432.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 684 shares during the period. Institutional investors own 90.60% of the company’s stock.
About Mesa Laboratories
Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.
The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.
Featured Stories
- Five stocks we like better than Mesa Laboratories
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
- How Does D-Wave’s New Simulator Change the Quantum Computing Landscape?
- Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock
- The Biotech Sector Looks Ready for a Multi-Year Breakout—Here’s What to Watch.
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
